Development of New Peptidomimetic NADPH Oxidase Inhibitors with Antithrombotic Properties
ChemMedChem · 2024
DOI: 10.1002/cmdc.202400330 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2024. Verfasst von Elisabetta Scalia und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry "Ugo Schiff", University of Florence, Via della Lastruccia 13, 50019, Sesto Fiorentino, Florence, Italy. Hauptthemen laut MEDLINE: Peptidomimetics, Fibrinolytic Agents, Enzyme Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intesa Sanpaolo Charity Fund, MUR - Dipartimenti di Eccellenza, Department of Chemistry "Ugo Schiff" of the University of Florence.
Abstract (Originalsprache)
The ability of synthetic peptides inhibitors of NOX1 to effectively block the production of ROS by the enzyme was studied with different methodologies. Specifically, taking advantage of our understanding of the active epitope of the regulatory NOX1 subunit NOXA1 as a potent inhibitor of NOX1‐derived O 2 ⋅ − formation, a panel of peptidomimetic derivatives of this peptide were designed and synthesized with the aim of improving their activity and increasing their stability in plasma. The results highlighted that improved efficacy and potency was found for both the peptide‐peptoid hybrid GS2 , whereas stapled peptide AC5 and its precursor showed higher stability despite lower biological potency. This study showed that minimal structural modifications of NOXA1 peptides are required to improve both their potency and stability to finally achieve best candidates as new potential anti‐thrombotic drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry "Ugo Schiff", University of Florence, Via della Lastruccia 13, 50019, Sesto Fiorentino, Florence, Italy.
- Department of Pharmacology and Chemical Biology, Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
- Institute for Clinical Chemistry and Laboratory Medicine, University Medical Center Eppendorf, Hamburg, Germany.
- Biomedical Institute for Multimorbidity, Hull York Medical School, Hull, UK.
ORCID-Profile: Lorenzo Calugi, Elena Lenci, Patrick J Pagano, Giordano Pula, Andrea Trabocchi
Förderung
- Intesa Sanpaolo Charity Fund
- MUR - Dipartimenti di Eccellenza
- Department of Chemistry "Ugo Schiff" of the University of Florence
Zitieren
APA
Scalia, E., Chirco, A., Calugi, L., Lenci, E., Pagano, P. J., Pula, G., & Trabocchi, A. (2024). Development of New Peptidomimetic NADPH Oxidase Inhibitors with Antithrombotic Properties. ChemMedChem. https://doi.org/10.1002/cmdc.202400330
Vancouver
Scalia E, Chirco A, Calugi L, Lenci E, Pagano PJ, Pula G, et al. Development of New Peptidomimetic NADPH Oxidase Inhibitors with Antithrombotic Properties. ChemMedChem. 2024. doi:10.1002/cmdc.202400330
BibTeX
@article{Scalia2024,
author = {Scalia, Elisabetta and Chirco, Antony and Calugi, Lorenzo and Lenci, Elena and Pagano, Patrick J and Pula, Giordano and Trabocchi, Andrea},
title = {Development of New Peptidomimetic NADPH Oxidase Inhibitors with Antithrombotic Properties},
journal = {ChemMedChem},
year = {2024},
doi = {10.1002/cmdc.202400330}
}
EUVIMED